Effectiveness of Glucocorticoid Therapy in COVID-19 Patients (Brief Review)

Ratiani Levan, Gabunia Luiza, Khetsuriani Shorena, Gamkrelidze Natia, Sulashvili Nodar


Glucocorticoid therapy is widely used among patients with different severe pulmonary inflammatory diseases. The novel study results recommend the use of corticosteroids for treatment of severe form of COVID-19 infection. Study results also indicate the importance of monitoring of these patients due to the possible adverse reactions of glucocorticoid therapy.


COVID-19 Infection, glucocorticoids, corticosteroids, adverse reactions, dexamethasone

Full Text:



Shuya Lu, Qi Zhou et al., Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Annals of Translational Medicine. Vol 8, No 10 (May 2020):

Lu Shuya,Zhou Qi ,HuangLiping, et al., on behalf of COVID-19 Evidence and Recommendations Working Group Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis Ann Transl Med. 2020 May; 8(10): 627.

Restellini S., Buyse S., Godat S., Goossens N., and Maillard M. H., “Management of gastrointestinal and hepatic diseases during the COVID-19 outbreak,” Revue Médicale Suisse, vol. 16, no. N° 691-2, pp. 845–848, 2020.

Glucocorticoid Therapy for Critically ill Patients with Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial. January 26, 2020https://www.clinicaltrials.gov/ct2/show/NCT04244591

Villar J, Confalonieri M, Pastores SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):e0111.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. 10.1016/S0140-6736(20)30251-8

So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-7. 10.1016/S0140-6736(03)13265-5

Arabi YM, Al-Omari A, Mandourah Y, et al. Saudi Critical Care Trial Group Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med 2017;45:1683-95.

Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine (Baltimore). 2019;98(26):e16239

Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–76.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5. 10.1016/S0140-6736(20)30317-2

Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683-4. 10.1016/S0140-6736(20)30361-5

Singh AK, Majumdar S, et al. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr. 2020;14(5):971–8.

Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne). 2020;7:170.

Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr 2020. [Epub ahead of print]. 10.1007/s12519-020-00345-5

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected [Internet]. World Health Organization March 2020 [cited 2020 Apr 13]. Available online: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf

Novel Coronavirus (2019-nCoV) Situation Report – 33 [Internet]. World Health Organization 2020 [cited 2020 Apr 13]. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19: preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.

Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020.

RECOVERY Collaborative Group; Peter Horby , Wei Shen Lim et al., Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report N Engl J Med. 2020 Jul 17;NEJMoa2021436.

Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–87.

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on dexamethasone. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. 16 June 2020. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

DOI: http://dx.doi.org/10.52155/ijpsat.v25.2.2847


  • There are currently no refbacks.

Copyright (c) 2021 Ratiani Levan, Gabunia Luiza, Khetsuriani Shorena, Gamkrelidze Natia, Sulashvili Nodar

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.